Donate Help Contact The AHA Sign In Home
American Heart Association
Arteriosclerosis, Thrombosis, and Vascular Biology
Search: search_blue_button Advanced Search
Arteriosclerosis, Thrombosis, and Vascular Biology. 1995;15:2019-2024

This Article
Right arrow Abstract Freely available
Right arrow Submit a response
Right arrow Alert me when this article is cited
Right arrow Alert me when eLetters are posted
Right arrow Alert me if a correction is posted
Right arrow Citation Map
Services
Right arrow Email this article to a friend
Right arrow Similar articles in this journal
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Download to citation manager
Right arrowRequest Permissions
Citing Articles
Right arrow Citing Articles via HighWire
Right arrow Citing Articles via Google Scholar
Google Scholar
Right arrow Articles by Parhami, F.
Right arrow Articles by Berliner, J. A.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Parhami, F.
Right arrow Articles by Berliner, J. A.
(Arteriosclerosis, Thrombosis, and Vascular Biology. 1995;15:2019-2024.)
© 1995 American Heart Association, Inc.


Articles

Stimulation of Gs and Inhibition of Gi Protein Functions by Minimally Oxidized LDL

Farhad Parhami; Zhuang T. Fang; Brian Yang; Alan M. Fogelman; Judith A. Berliner

From the Departments of Medicine (F.P., A.M.F., J.A.B.) and Pathology (Z.T.F., B.Y., J.A.B.), UCLA School of Medicine, Los Angeles, Calif.

Correspondence to Farhad Parhami, Division of Cardiology, UCLA Center for Health Sciences, Rm 47-123, 10833 Le Conte Ave, Los Angeles, CA 90095.


*    Abstract
up arrowTop
*Abstract
down arrowIntroduction
down arrowMethods
down arrowResults
down arrowDiscussion
down arrowReferences
 
Abstract We have previously shown that treatment of aortic endothelial cells with minimally oxidized LDL (MM-LDL) induces their interaction with monocytes but not neutrophils and that these induced responses are associated with increased cAMP levels. Here we studied the mechanism by which MM-LDL elevates cAMP levels. Treatment of human aortic endothelial cells with MM-LDL resulted in a saturable dose-dependent increase in cAMP levels. Studies using a combination of pertussis toxin and MM-LDL suggested that part of the cAMP increase was due to the stimulation of Gs complexes. Studies with pertussis toxin–treated membranes in which Gi was completely inhibited were used to directly address the effect of MM-LDL on the Gs pathway. MM-LDL and an oxidized lipid (palmitoyl arachidonyl phosphatidylcholine), the effects of which mimic those of MM-LDL, caused a 40% to 100% increase in cAMP levels in these isolated membranes that was augmented by GTP, thus showing Gs stimulation. These results also show that MM-LDL increases cAMP levels by inhibiting Gi. MM-LDL inhibited ADP ribosylation of Gi by about 30% and completely abolished the ability of serotonin to interact with Gi complexes, whereas direct activation of Gi by mastoparan was not inhibited. This observation suggests that MM-LDL interferes with the interaction of Gi molecules with inhibitory receptors. There was no direct effect of MM-LDL on adenylate cyclase. Overall, these studies show that MM-LDL increases cAMP levels both by stimulating Gs and inhibiting Gi complexes.


Key Words: minimally oxidized LDL • G proteins • cAMP • ADP ribosylation


*    Introduction
up arrowTop
up arrowAbstract
*Introduction
down arrowMethods
down arrowResults
down arrowDiscussion
down arrowReferences
 
Oxidized lipoproteins may play an important role in the pathogenesis of atherosclerosis, as shown by their presence in human lesions,1 as well as the ability of antioxidants to reduce lipoprotein oxidation and lesion formation.2 An important early event in the initiation of atherosclerosis is the increased interaction of monocytes with ECs lining the vessel wall.3 MM-LDL prepared by mild oxidation of LDL has substantial atherogenic properties, including its ability to induce endothelium-monocyte interactions.4 5 The biological activity of MM-LDL is highly associated with the elevation of cAMP levels in aortic ECs.6 In fact, cholera toxin, an activator of Gs; PT, an inhibitor of Gi; IP, a ß-adrenergic receptor agonist; and dibutyryl cAMP, all of which elevate intracellular cAMP levels, elicit responses similar to those induced by MM-LDL.6 In the present study we have characterized the mechanism by which MM-LDL elevates cAMP levels.

Many review articles have described the regulatory mechanisms for the activity of AC, the family of enzymes responsible for cAMP formation in cells.7 8 Briefly, AC activity is regulated by the Gs-mediated stimulatory and Gi-mediated inhibitory arms of the AC system.7 The activation of Gs complexes occurs as the result of interaction with a ligand-bound stimulatory receptor, followed by the dissociation of the {alpha} subunit from the ß and {gamma} subunits and the activation of AC by these subunits. The dissociation of the subunits involves the exchange of a GDP for a GTP molecule, hence the GTP dependence of the activation process. Inhibition of AC occurs via a similar pathway mediated by the dissociation of the {alpha} subunit of Gi complexes from their ß and {gamma} subunits. In several systems AC activity is under tonic inhibition by Gi complexes.9 10 Inhibition of these Gi complexes by PT-catalyzed ADP ribosylation of their {alpha} subunit leads to the potentiation of the effects of the stimulatory arm of the AC system as well as the elevation of basal cAMP levels.9 10 The G protein–independent alteration of AC activity due to changes in the physical characteristics of cellular plasma membrane after lipid incorporation has also been reported.11 12 The present study addresses the following questions. Does MM-LDL cause the receptor-mediated activation of Gs complexes, thereby causing the stimulation of AC activity? Does MM-LDL impair the function of Gi complexes, thus potentiating the stimulation of AC? Does MM-LDL affect the activity of AC independent of the effects on G proteins?


*    Methods
up arrowTop
up arrowAbstract
up arrowIntroduction
*Methods
down arrowResults
down arrowDiscussion
down arrowReferences
 
Cell and Lipoprotein Preparation and Modification
HAECs at passages 5 through 8 were prepared.13 Human LDL was isolated by density-gradient centrifugation of serum and stored in phosphate-buffered 0.15 mol/L NaCl containing 0.01% EDTA.

MM-LDL was made by enzymatic modification by using soybean lipoxygenase and phospholipase A26 or by mild oxidation with iron.6 The preparations of MM-LDL used for these studies contained between 20 and 50 pg lipopolysaccharide/mL medium. Both methods of MM-LDL preparation caused minimal oxidation, giving 2 to 3 nmol of thiobarbituric acid–reactive substances per milligram of cholesterol after dialysis. The concentrations of lipoproteins used in this study are reported in micrograms of protein. The two methods of lipoprotein modification gave preparations of MM-LDL with similar activity. Each preparation of modified lipoprotein was used at a concentration determined to elicit maximal cellular response.

cAMP Measurement
HAECs were cultured in six-well dishes, and cells were treated with or without agonists in medium 199 containing 5% fetal calf serum and 82 µmol/L IBMX (Calbiochem Corp), a phosphodiesterase inhibitor. After incubation, the cells were rinsed twice with phosphate-buffered saline containing 4 mmol/L EDTA (also an inhibitor of cAMP phosphodiesterase) and scraped into the same buffer. The cell pellet after centrifugation was resuspended in 200 µL boiling assay buffer (cAMP RIA kit, Amersham Corp). The suspension was sonicated, heated 5 minutes in a boiling-water bath, and microcentrifuged for 3 minutes at high speed to spin out the coagulated proteins. The supernatant was used to determine cAMP levels normalized to cell number.

Membrane Preparation
HAECs were cultured in 100-mm dishes, and cells were left untreated or treated with agonist in medium 199 containing 5% fetal calf serum. Membrane was prepared by one of the following methods, both of which gave similar results when used in assays. Crude membrane preparation was made by rinsing the cells twice with cold phosphate-buffered saline containing 0.1 mmol/L PMSF (a protease inhibitor; Sigma), after which the cells were scraped into the same buffer. After centrifugation the cell pellet was resuspended in 250 µL of 10 mmol/L Tris-HCl buffer, pH 7.5, containing 1 mmol/L dithiothreitol, 0.1 mmol/L PMSF, 1 µmol/L each pepstatin and leupeptin (protease inhibitors; Sigma), 5 mmol/L MgCl2, and 1 mmol/L EDTA. The resuspended cell pellet was then subjected to three rounds of freeze-thawing in dry ice–ethanol to disrupt the cells. The suspension was microcentrifuged at 4°C for 10 minutes at 14 000g to obtain the pellet designated as the membrane fraction. The pellet was resuspended in 100 mmol/L potassium phosphate buffer, pH 7.5, containing 5 mmol/L MgCl2 and PMSF, pepstatin, and leupeptin at the same concentrations as before. The suspension was then sonicated for 10 seconds, and aliquots were used for protein determination. As an alternate method, partially purified membrane fractions were prepared by collecting the cell pellet as described above and freeze/thawing to disrupt the cells. The cells were centrifuged for 5 minutes at 500g to separate cellular organelles, and the supernatant from the first spin was further centrifuged for 10 minutes at 4°C at 14 000g to obtain the partially purified membrane pellet.

AC Assay
HAEC membranes were prepared as described above. Assay buffer consisting of 50 mmol/L Tris-HCl, pH 7.5, 1 mmol/L IBMX, 1.5 mmol/L EDTA, 1 mmol/L dithiothreitol, 5 mmol/L MgCl2, 0.25% bovine serum albumin, and 0.1 mmol/L PMSF was put in all assay tubes for a total reaction volume of 100 µL. ATP (Sigma) was added to all tubes (final concentration, 1 mmol/L). GTP was also added to each tube (final concentration, 0.5 mmol/L). GTP was also added to each tube (final concentration, 0.5 unless stated otherwise). If testing the ability of MM-LDL, IP, or PAPC to activate AC, these agonists were also added to the appropriate tubes. Finally, 5 µg membrane preparation was placed in each assay tube (except in the control tube that lacked membrane). Tubes were incubated for 15 minutes at 30°C, after which the reaction was stopped by adding 800 µL boiling cAMP assay buffer and heating for 5 minutes in a boiling-water bath. The tubes were then microcentrifuged for 3 minutes at high speed to spin out the coagulated proteins, and the supernatant was used to determine cAMP content as described above. This method measures the amount of cAMP formed as determined by RIA, in contrast to the formation of labeled cAMP derived from labeled ATP as used by other investigators. In addition, the present method does not require the separation of labeled cAMP from ATP due to the specificity of the RIA system.

ADP Ribosylation
HAEC membranes were prepared as described above. Membrane preparation (15 µg) was placed in each assay tube, except in the control tube without membrane. Assay buffer was added that consisted of 100 mmol/L potassium phosphate, 5 mmol/L MgCl2, 0.1 mmol/L PMSF, 1 µmol/L each leupeptin and pepstatin, 10 mmol/L dithiothreitol, 4 mmol/L thymidine, 1 mmol/L ATP, 1 mmol/L GTP, and 20 µg ovalbumin for a total volume of 200 µL. To each tube 8 µCi (0.2 µmol/L) nicotinamide adenine[{alpha}-32P]dinucleotide (ICN Radiochemicals) and 2.5 µg/mL activated PT (Calbiochem) were added. PT was activated by incubation at 25 µg/mL in 20 mmol/L dithiothreitol at 30°C for 15 minutes. Tubes were incubated for 30 minutes at 30°C, and the reaction was stopped by the addition of 800 µL ice-cold 13% TCA. TCA-precipitated pellets were obtained by microcentrifugation at 14 000g for 10 minutes at 4°C; the pellets were rinsed once with 13% TCA and twice with cold acetone. The acetone was discarded, and the pellets were dissolved in SDS loading buffer, heated for 10 minutes in a boiling-water bath, and analyzed in an 11% gel by using SDS-PAGE followed by autoradiography. The signals were analyzed by densitometric scanning and are reported in relative densitometric units that describe the extent of ADP ribosylation in each sample.

Western Blotting
Membrane fractions were prepared as described above, and 15 µg was resuspended in SDS buffer containing ß-mercaptoethanol. Proteins were separated by using PAGE and transferred to nitrocellulose membrane. The membrane was then incubated with antibody to Gi{alpha}1,2 (Biodesign International), and antibody was detected by chemiluminescence by using the Amersham ECL reaction system. A band at 41 Kd was detected that corresponds to the position of Gi{alpha}2.


*    Results
up arrowTop
up arrowAbstract
up arrowIntroduction
up arrowMethods
*Results
down arrowDiscussion
down arrowReferences
 
Elevation of cAMP Levels by MM-LDL
Incubation of HAECs for 4 hours with MM-LDL resulted in a saturable dose-dependent increase in cAMP levels (Fig 1Down). This saturation point was below the level produced with cholera toxin, suggesting a saturable process other than the saturation of the AC machinery.



View larger version (12K):
[in this window]
[in a new window]
 
Figure 1. Line graph showing that MM-LDL induces a dose-dependent increase in cAMP levels. HAECs were incubated at 37°C with the indicated concentration of MM-LDL for 4 hours in the presence of 82 µmol/L IBMX. cAMP levels were measured by using an RIA kit (Amersham Corp). The results are from a representative experiment reported as the mean of duplicate determinations with <5% difference between the duplicates.

MM-LDL Does Not Directly Activate AC
Because one mechanism by which MM-LDL may elevate cAMP levels is by a G protein–independent activation of AC, we examined the activity of the enzyme in membrane preparations from untreated cells and cells treated with MM-LDL in the absence of exogenously added GTP or stimulatory agonists. No increase in AC activity was detected in membrane preparations from MM-LDL–treated versus untreated control cells (4.1 versus 4.2 fmol cAMP·mg-1·min-1, respectively; n=6, P=.447). These data suggest that MM-LDL does not directly activate AC in these cells.

Activation of Gs by MM-LDL
To examine the role of Gs in activation of AC by MM-LDL, several approaches were taken. To detect Gs-specific increases in AC activity, the possible contribution from MM-LDL–induced Gi inhibition must be eliminated. This was achieved by using PT, an enzyme that has been shown to inhibit receptor–Gi protein interaction by ADP-ribosylating the Gi {alpha} subunits.14 Incubation of HAECs for 4 hours with 1 µg/mL PT or 125 µg/mL MM-LDL but not native LDL caused significant elevation of cAMP levels (Fig 2Down). Preincubation with 1 µg/mL PT for 4 hours caused the complete inhibition of ADP ribosylation by PT (Fig 2Down), an indication of maximal inhibition of all possible receptor-Gi interactions.15 When cells were treated for 4 hours with both 1 µg/mL PT and 125 µg/mL MM-LDL, an additional increase of 32% in cAMP levels was observed compared with that induced by PT alone (P<.005 for PT plus MM-LDL versus PT); native LDL did not have an effect similar to MM-LDL (Fig 2Down). IP, a ß-adrenergic receptor agonist that activates AC via activation of Gs, also caused an increase in cAMP levels when added in combination with PT, although the increase was much greater than that seen for MM-LDL (Fig 2Down).



View larger version (57K):
[in this window]
[in a new window]
 
Figure 2. Top, Bar graph showing MM-LDL–induced cAMP elevation in cells maximally stimulated with PT. HAECs were incubated for 4 hours at 37°C with 125 µg/mL MM-LDL (MM), 125 µg/mL native LDL (NL), 1 µg/mL PT, or 5 µmol/L IP alone or in the combinations indicated in the presence of 82 µmol/L IBMX. cAMP levels were measured after the incubations. Results are the percent increase in cAMP levels compared with untreated cells (*P<.005 PT vs PT+MM or PT+IP; P=.555 PT vs PT+NL). Values are mean±SEM and are representative of three experiments, each with four determinations. Bottom, HAECs were incubated for 4 hours at 37°C with (+) or without (-) 1 µg/mL PT. ADP ribosylation was performed on membrane preparations from these cells as described in "Methods."

Activation of AC by MM-LDL Is GTP Dependent
To further determine whether MM-LDL increased cAMP by a Gs-dependent activation of AC activity, membranes were isolated from HAECs pretreated with 20 ng/mL PT for 4 hours to inhibit Gi complexes. This two-step isolation (described in "Methods") resulted in partially purified membranes that showed no further ADP ribosylation by PT, indicating the complete inhibition of Gi. GTP (0.5 mmol/L), MM-LDL (500 µg/mL), oxidized PAPC, or IP were added separately or in combination with the membrane preparations for 15 minutes, and cAMP synthesis was measured by RIA (Fig 3Down). Oxidized PAPC was used because in a separate study we have shown that the major activity of MM-LDL is derived from oxidized PAPC.24 GTP caused an {approx}40% increase in cAMP synthesis in isolated membranes. Both MM-LDL and oxidized PAPC in the absence of GTP caused increases in cAMP levels formed. The addition of GTP to PAPC or MM-LDL caused additional 85% and 40% increases in AC activity, respectively, compared with those induced in the absence of exogenous GTP. IP increased AC activity twofold in the absence and sevenfold in the presence of GTP compared with control membranes (data not shown). Overall, these data show that MM-LDL and oxidized PAPC stimulate cAMP synthesis by a Gs-mediated pathway.



View larger version (74K):
[in this window]
[in a new window]
 
Figure 3. Bar graph showing that MM-LDL (MM) caused a GTP-dependent increase in cAMP levels. Partially purified membranes were isolated from HAECs treated for 4 hours with PT (20 ng/mL). These membrane preparations were incubated for 15 minutes at 30°C with GTP (0.5 mmol/L), MM-LDL (500 µg/mL), or oxidized PAPC (100 µg/mL) either alone or in the combinations indicated. The incubation buffer contained 1 mmol/L IBMX, 1.5 mmol/L EDTA, and 1 mmol/L ATP. Levels of cAMP were measured by using an RIA. Data are mean±SD from the mean of duplicate samples and are representative of three experiments, all of which indicated increased AC activity compared with control membrane AC activity.

Effects of MM-LDL on Gi Molecules
The effect of MM-LDL treatment of ECs was also examined. Western blot analysis of HAEC membranes using an antibody to Gi{alpha}2 detected a band at 41 Kd (Fig 4Down). In two separate experiments, incubation of cells for 4 hours with 125 µg/mL MM-LDL had no effect on the levels of membrane-associated Gi{alpha}2; however, in those same experiments ADP ribosylation of Gi{alpha}2 by PT was inhibited by 54% (Fig 5Down). MM-LDL–induced inhibition ranged between 40% and 60% in five different experiments. Similarly, incubation of cells with 1 µg/mL PT caused a 95% inhibition of ADP ribosylation by PT (Fig 5Down). In addition, inhibition of PT-catalyzed ADP ribosylation of an 80-Kd protein was observed following MM-LDL treatment. The identity of this molecule, which was not immunoreactive with the antibody to Gi{alpha}2, is presently unknown to us.



View larger version (15K):
[in this window]
[in a new window]
 
Figure 4. Western blot showing that MM-LDL does not alter the levels of membrane-associated Gi{alpha}2. HAECs were treated for 4 hours with (MM) or without (C) MM-LDL (250 µg/mL), and partially purified membranes were prepared as described in "Methods." Western blot analysis was performed by using antibody to Gi{alpha}1,2. Results are representative of two experiments that are shown in duplicate lanes.



View larger version (54K):
[in this window]
[in a new window]
 
Figure 5. Bar graph showing that ADP ribosylation by PT is inhibited by pretreatment of cells with MM-LDL. HAECs were incubated for 4 hours at 37°C with no additives (C), 1 µg/mL PT, 125 µg/mL MM-LDL (MM), or 125 µg/mL native LDL (NL). ADP ribosylation was performed on 15 µg membrane preparation from these cells followed by SDS-PAGE analysis and autoradiography of the TCA-precipitated proteins. The signals were traced on a densitometer. The data from a representative experiment are reported as the mean of duplicate samples expressed as relative ADP ribosylation compared with control (percent of control). Error bars indicate the percent difference between duplicate samples.

MM-LDL Pretreatment Inhibits Receptor-Mediated Activation of Gi by Serotonin
To further characterize the effect of MM-LDL on Gi activity, the ability of serotonin and mastoparan to activate Gi molecules in membrane preparations from untreated versus MM-LDL–treated cells was tested. PT only ADP ribosylates Gi molecules in their trimeric form, and receptor-mediated activation of Gi by agonists such as serotonin or activation by direct Gi activators such as mastoparan results in dissociation of the {alpha} subunit from the ß and {gamma} subunits, thereby inhibiting ADP ribosylation.14 Previous reports have examined the interaction of membrane receptors with Gi molecules by assessing the inhibition of PT-catalyzed ADP ribosylation of Gi.16 Incubation of membranes from untreated HAECs with serotonin resulted in a 60% inhibition of ADP ribosylation by PT (Fig 6Down). However, serotonin did not inhibit ADP ribosylation in membrane preparations from MM-LDL–treated cells (Fig 6Down). Although in several experiments the degree of MM-LDL effect varied depending on the activity of the MM-LDL preparation used, there was always an inhibitory effect on the ability of serotonin to activate Gi molecules. Mastoparan caused a 95% inhibition of PT-catalyzed ADP ribosylation in membrane preparations of untreated cells. In contrast to serotonin, the ability of mastoparan to activate Gi molecules and inhibit ADP ribosylation was not inhibited in membrane preparations from MM-LDL–treated cells (Fig 7Down).



View larger version (61K):
[in this window]
[in a new window]
 
Figure 6. Bar graph showing that MM-LDL (MM) inhibits the activation of Gi by serotonin (SR). HAECs were incubated for 4 hours at 37°C with no additives (C) or with 125 µg/mL MM-LDL. Next, 15 µg membrane preparation from these cells was subjected to 10-4 mol/L serotonin activation (+SR) for 5 minutes at 30°C followed by ADP ribosylation with PT. TCA-precipitated proteins were analyzed by SDS-PAGE and autoradiography. Results are representative of three experiments. Signals were traced on a densitometer and are reported as the mean of duplicate samples expressed as percent of control, with error bars representing the percent difference between duplicate samples.



View larger version (46K):
[in this window]
[in a new window]
 
Figure 7. Bar graph showing that MM-LDL (MM) does not inhibit the activation of Gi by mastoparan (MP). HAECs were incubated for 4 hours at 37°C with no additives (C) or with 125 µg/mL MM-LDL. Next, 15 µg membrane preparation from these cells was subjected to 10 µmol/L mastoparan activation for 5 minutes at 30°C followed by ADP ribosylation with PT. TCA-precipitated proteins were analyzed by SDS-PAGE and autoradiography. The signals were traced on a densitometer; data are representative of three experiments and are reported as the mean of duplicate samples expressed as percent of control. Error bars represent percent difference between duplicate samples.


*    Discussion
up arrowTop
up arrowAbstract
up arrowIntroduction
up arrowMethods
up arrowResults
*Discussion
down arrowReferences
 
Exposure of aortic ECs to MM-LDL induced a saturable dose-dependent elevation of intracellular cAMP levels (Fig 1Up). Several lines of evidence suggest that MM-LDL activates the stimulatory arm of the AC system mediated by Gs molecules. Under experimental conditions in which PT caused maximal inhibition of Gi protein activity and in the presence of the phosphodiesterase inhibitor IBMX, MM-LDL had an additive effect with PT in causing the elevation of cAMP levels, whereas native LDL was ineffective (Fig 2Up). Further evidence for the involvement of Gs in mediating the MM-LDL–induced AC stimulation came from the observation that treatment of EC membrane preparations (in which Gi complexes were completely inhibited) caused a significant elevation of AC activity (Fig 3Up). This increase was further augmented by the presence of GTP. There was no direct effect of MM-LDL on AC. The similarity of the action of MM-LDL to IP, in addition to the saturability of the MM-LDL effect, may indicate the presence of a Gs-linked, membrane-bound receptor for MM-LDL on aortic ECs. It must be noted that direct evidence for the existence of a receptor for MM-LDL requires confirmation. The putative MM-LDL receptor is not the same as the LDL receptor, since this receptor is not Gs coupled. The MM-LDL receptor may be one of the identified Gs-coupled lipid receptors or a related receptor, since lipids from MM-LDL can cause effects similar to the intact lipoprotein,4 and in this study we showed that an oxidized lipid that mimics the effect of MM-LDL caused a Gs-mediated increase in AC activity (Fig 3Up).

The activation of Gs molecules appears to be a partial explanation of the mechanism by which MM-LDL elevates cAMP levels in aortic ECs. Our present study indicates that MM-LDL causes several effects on endothelial Gi molecules. Incubation of ECs with MM-LDL but not native LDL significantly inhibited PT-catalyzed ADP ribosylation of Gi (Fig 5Up). The mechanism by which MM-LDL may cause such an effect is not known; however, posttranslational modification of the Gi molecules may be involved. One possibility may be the activation of a cellular ADP ribosyltransferase17 that would ADP ribosylate the sites normally targeted by PT. Activation of cellular ADP ribosyltransferases has been reported for other EC activators, such as L-arginine,18 the precursor of endothelium-derived nitric oxide, a potent vasodilator. Alternatively, MM-LDL may alter the PT binding sites, thereby blocking their interaction with PT. The effect of MM-LDL is not due to a decrease in the total amount of membrane-associated Gi{alpha}2 (Fig 4Up).

Our observations also indicate that MM-LDL interferes with receptor activation of Gi molecules, as suggested by the complete inhibition of serotonin-induced Gi activation and PT-catalyzed ADP ribosylation in membranes from MM-LDL–treated cells (Fig 6Up). This effect appears to be specifically at the level of Gi-receptor interaction, since the direct activation of Gi by mastoparan was not affected (Fig 4Up). MM-LDL may inhibit the site of interaction with inhibitory receptors, which may be close if not similar to the site of ADP ribosylation by PT. Impaired Gi-mediated function of the endothelium from atherosclerotic vessels has been reported.19 Similar results have been reported for the ability of lysophosphatidylcholine, a component of oxidized LDL, to inhibit receptor-mediated activation of Gi molecules in ECs.20 Lysophosphatidylcholine is unlikely to be responsible for inhibition of ADP ribosylation by MM-LDL, as by itself it does not increase cAMP levels in HAECs, and very low levels of lysophosphatidylcholine are present in the iron-oxidized LDL used for several of the ADP ribosylation studies (less than 1 µmol/L when MM-LDL is added to the cells at 125 µg/mL). In addition, Liao21 has shown the inhibition of bradykinin-stimulated, Gi-mediated release of nitric oxide in bovine aortic ECs treated for 72 hours with LDL. This effect may have been caused as a result of cell-mediated oxidation of LDL. Liao and Clark22 have further reported that such prolonged treatment of cells with LDL oxidized to a greater degree than the LDL used in the present studies causes a decrease in the level of expression of Gi{alpha}2. Thus, the results of previous studies and the present one show that Gi inhibition in response to products of lipid oxidation may only involve alterations in the interaction of receptors with Gi complexes or may, under more severe conditions, involve actual loss of the Gi protein. An extensive review by Flavahan23 describes the potential mechanisms underlying the impaired Gi-mediated endothelial signaling associated with atherosclerosis.

We have identified an oxidized phospholipid in MM-LDL that is responsible for its ability to induce monocyte adherence to ECs and that is a target for inactivation by the platelet-activating factor acetylhydrolase.24 Our preliminary observations suggest that the phospholipids isolated from MM-LDL elevate cAMP levels in aortic ECs. We are currently further characterizing the active lipid components in MM-LDL that are responsible for stimulating AC activity. Here we have presented evidence that MM-LDL activates aortic ECs by interacting with their Gs as well as their Gi molecules. If the present in vitro study indicates the events occurring in vivo, our observations suggest that several pathways would need to be targeted to control endothelial activation in atherosclerosis.


*    Selected Abbreviations and Acronyms
 
AC = adenylate cyclase
EC = endothelial cell
HAEC = human aortic endothelial cell
IBMX = 3-isobutyl-1-methylxanthine
MM-LDL = minimally oxidized LDL
PAGE = polyacrylamide gel electrophoresis
PAPC = palmitoyl arachidonyl phosphatidylcholine
PMSF = phenylmethylsulfonyl fluoride
PT = pertussis toxin
RIA = radioimmunoassay
SDS = sodium dodecyl sulfate
TCA = trichloroacetic acid


*    Acknowledgments
 
This research was supported by National Institutes of Health grants HL-30568, MO1 RR00865, and TRDRP RT372 and the Laubisch Fund. The authors thank Dr Nicholas A. Flavahan for his expert advice.

Received January 11, 1995; accepted September 1, 1995.


*    References
up arrowTop
up arrowAbstract
up arrowIntroduction
up arrowMethods
up arrowResults
up arrowDiscussion
*References
 
1. Yla-Herttuala S, Palinski W, Rosenfeld ME, Parthasarathy S, Carew TE, Butler S, Witztum JL, Steinberg D. Evidence for the presence of oxidatively modified low density lipoprotein in atherosclerotic lesions of rabbit and man. J Clin Invest. 1989;84:1086-1095.

2. Kita T, Nagano Y, Yokode M, Ishii K, Kume N, Ooshima A, Yoshida H, Kawai C. Probucol prevents the progression of atherosclerosis in Watanabe heritable hyperlipidemic rabbit, an animal model for familial hyperlipidemia. Proc Natl Acad Sci U S A. 1987;84:5928-5931. [Abstract/Free Full Text]

3. Ross R. The pathogenesis of atherosclerosis: an update. N Engl J Med. 1986;314:488-500. [Medline] [Order article via Infotrieve]

4. Berliner JA, Territo MC, Sevanian A, Ramin S, Kim JA, Bamshad B, Esterson M, Fogelman AM. Minimally modified low density lipoprotein stimulates monocyte endothelial interactions. J Clin Invest. 1990;85:1260-1266.

5. Cushing SD, Berliner JA, Valentine AJ, Territo MC, Navab M, Parhami F, Gerrity R, Schwarz CJ, Fogelman AM. Minimally modified low density lipoprotein induces monocyte chemotactic protein 1 in human endothelial cells and smooth muscle cells. Proc Natl Acad Sci U S A. 1990;87:5134-5138. [Abstract/Free Full Text]

6. Parhami F, Fang ZT, Fogelman AM, Andalibi A, Territo MC, Berliner JA. Minimally modified low density lipoprotein-induced inflammatory responses in endothelial cells are mediated by cyclic adenosine monophosphate. J Clin Invest. 1993;92:471-478.

7. Reithmann C, Gierschik P, Jacobs KH. Stimulation and inhibition of adenylate cyclase. Symp Soc Exp Biol. 1990;44:207-224. [Medline] [Order article via Infotrieve]

8. Tang WJ, Gilman AG. Adenylyl cyclases. Cell. 1992;70:869-872. [Medline] [Order article via Infotrieve]

9. Hsia JA, Moss J, Hewlett EL, Vaughan M. Requirement for both choleragen and pertussis toxin to obtain maximal activation of adenylate cyclase in cultured cells. Biochem Biophys Res Commun. 1984;119:1068-1074. [Medline] [Order article via Infotrieve]

10. Olansky L, Myers GA, Pohl SL, Hewlett EL. Promotion of lipolysis in rat adipocytes by pertussis toxin, reversal of endogenous inhibition. Proc Natl Acad Sci U S A. 1983;80:6547-6551. [Abstract/Free Full Text]

11. Laychock SG. Coordinate interaction of cyclic nucleotide phospholipid metabolizing pathways in calcium-dependent cellular responses. Curr Top Cell Regul. 1989;30:203-242. [Medline] [Order article via Infotrieve]

12. Engelhard VH, Esko JD, Storm DR, Glaser M. Modification of adenylate cyclase activity in LM cells by manipulation of membrane phospholipid composition in vivo. Proc Natl Acad Sci U S A. 1976;73:4482-4486. [Abstract/Free Full Text]

13. Berliner JA, Territo MC, Almada L, Carter A, Shafonsky E, Fogelman AM. Monocyte chemotactic factor produced by large-vessel endothelial cells in vitro. Arteriosclerosis. 1986;6:254-258. [Abstract/Free Full Text]

14. Moss J, Vaughan M. ADP-ribosylation of guanyl nucleotide-binding regulatory proteins by bacterial toxins. Adv Enzymol Relat Areas Mol Biol. 1988;61:303-379. [Medline] [Order article via Infotrieve]

15. Gold MR, Jakway JP, DeFranco AL. Involvement of a guanine-nucleotide-binding component in membrane IgM-stimulated phosphoinositide breakdown. J Immunol. 1987;139:3604-3613. [Abstract]

16. Wilhelm B, Siess W. Activation of cloned platelet thrombin receptor decreases the pertussis-toxin-dependent ADP-ribosylation of the membrane and soluble inhibitory guanine-nucleotide-binding-{alpha} proteins. Eur J Biochem. 1993;216:81-88. [Medline] [Order article via Infotrieve]

17. Ueda K. ADP-ribosylation. Annu Rev Biochem. 1985;54:73-100. [Medline] [Order article via Infotrieve]

18. Dimmeler S, Brune B. L-arginine stimulates an endogenous ADP-ribosyltransferase. Biochem Biophys Res Commun. 1991;178:848-855. [Medline] [Order article via Infotrieve]

19. Shimokawa H, Flavahan NA, Vanhoutte PM. Loss of endothelial pertussis toxin–sensitive G protein function in atherosclerotic porcine coronary arteries. Circulation. 1991;83:652-660. [Abstract/Free Full Text]

20. Flavahan NA. Lysophosphatidylcholine modifies G protein-dependent signaling in porcine endothelial cells. Am J Physiol. 1993;264:H722-H727.[Abstract/Free Full Text]

21. Liao JK. Inhibition of Gi proteins by low density lipoprotein attenuates bradykinin-stimulated release of endothelial-derived nitric oxide. J Biol Chem. 1994;269:12987-12992. [Abstract/Free Full Text]

22. Liao JK, Clark SL. Regulation of G-protein ai2 subunit expression by oxidized low-density lipoprotein. J Clin Invest. 1995;95:1457-1463.

23. Flavahan NA. Atherosclerosis or lipoprotein-induced endothelial dysfunction: potential mechanisms underlying reduction in EDRF/nitric oxide activity. Circulation. 1992;85:1927-1938. [Free Full Text]

24. Watson AD, Navab M, Hama SY, Sevanian A, Prescott SM, Stafforini DM, McIntyre TM, La Du BN, Fogelman AM, Berliner JA. Effect of platelet activating factor-acetylhydrolase on the formation and action of minimally oxidized low density lipoprotein. J Clin Invest. 1995;95:774-782.




This article has been cited by other articles:


Home page
J. Lipid Res.Home page
J. Huber, A. Furnkranz, V. N. Bochkov, M. K. Patricia, H. Lee, C. C. Hedrick, J. A. Berliner, B. R. Binder, and N. Leitinger
Specific monocyte adhesion to endothelial cells induced by oxidized phospholipids involves activation of cPLA2 and lipoxygenase
J. Lipid Res., May 1, 2006; 47(5): 1054 - 1062.
[Abstract] [Full Text] [PDF]


Home page
Circ. Res.Home page
N. Leitinger
A Rancid Culprit in Vascular Inflammation Acts on the Prostaglandin Receptor EP2
Circ. Res., March 17, 2006; 98(5): 587 - 589.
[Full Text] [PDF]


Home page
Circ. Res.Home page
R. Li, K. P. Mouillesseaux, D. Montoya, D. Cruz, N. Gharavi, M. Dun, L. Koroniak, and J. A. Berliner
Identification of Prostaglandin E2 Receptor Subtype 2 As a Receptor Activated by OxPAPC
Circ. Res., March 17, 2006; 98(5): 642 - 650.
[Abstract] [Full Text] [PDF]


Home page
EndocrinologyHome page
D. Liu, H. Jiang, and R. W. Grange
Genistein Activates the 3',5'-Cyclic Adenosine Monophosphate Signaling Pathway in Vascular Endothelial Cells and Protects Endothelial Barrier Function
Endocrinology, March 1, 2005; 146(3): 1312 - 1320.
[Abstract] [Full Text] [PDF]


Home page
Arterioscler. Thromb. Vasc. Bio.Home page
A. L. Cole, G. Subbanagounder, S. Mukhopadhyay, J. A. Berliner, and D. K. Vora
Oxidized Phospholipid-Induced Endothelial Cell/Monocyte Interaction Is Mediated by a cAMP-Dependent R-Ras/PI3-Kinase Pathway
Arterioscler Thromb Vasc Biol, August 1, 2003; 23(8): 1384 - 1390.
[Abstract] [Full Text] [PDF]


Home page
Arterioscler. Thromb. Vasc. Bio.Home page
N. Mackman
How Do Oxidized Phospholipids Inhibit LPS Signaling?
Arterioscler Thromb Vasc Biol, July 1, 2003; 23(7): 1133 - 1136.
[Full Text] [PDF]


Home page
FASEB J.Home page
I. GOUNI-BERTHOLD and A. SACHINIDIS
Does the coronary risk factor low density lipoprotein alter growth and signaling in vascular smooth muscle cells?
FASEB J, October 1, 2002; 16(12): 1477 - 1487.
[Abstract] [Full Text] [PDF]


Home page
CirculationHome page
I. Escargueil-Blanc, R. Salvayre, N. Vacaresse, G. Jurgens, B. Darblade, J.-F. Arnal, S. Parthasarathy, and A. Negre-Salvayre
Mildly Oxidized LDL Induces Activation of Platelet-Derived Growth Factor {beta}-Receptor Pathway
Circulation, October 9, 2001; 104(15): 1814 - 1821.
[Abstract] [Full Text] [PDF]


Home page
Am. J. Physiol. Heart Circ. Physiol.Home page
T. Tanikawa, H. Kanatsuka, R. Koshida, M. Tanaka, A. Sugimura, T. Kumagai, M. Miura, T. Komaru, and K. Shirato
Role of pertussis toxin-sensitive G protein in metabolic vasodilation of coronary microcirculation
Am J Physiol Heart Circ Physiol, October 1, 2000; 279(4): H1819 - H1829.
[Abstract] [Full Text] [PDF]


Home page
CirculationHome page
W. Shi, M. E. Haberland, M.-L. Jien, D. M. Shih, and A. J. Lusis
Endothelial Responses to Oxidized Lipoproteins Determine Genetic Susceptibility to Atherosclerosis in Mice
Circulation, July 4, 2000; 102(1): 75 - 81.
[Abstract] [Full Text] [PDF]


Home page
J. Cell Sci.Home page
A. Paulson, P. Lampe, R. Meyer, E TenBroek, M. Atkinson, T. Walseth, and R. Johnson
Cyclic AMP and LDL trigger a rapid enhancement in gap junction assembly through a stimulation of connexin trafficking
J. Cell Sci., January 9, 2000; 113(17): 3037 - 3049.
[Abstract] [PDF]


Home page
Arterioscler. Thromb. Vasc. Bio.Home page
L. J. Pinderski Oslund, C. C. Hedrick, T. Olvera, A. Hagenbaugh, M. Territo, J. A. Berliner, and A. I. Fyfe
Interleukin-10 Blocks Atherosclerotic Events In Vitro and In Vivo
Arterioscler Thromb Vasc Biol, December 1, 1999; 19(12): 2847 - 2853.
[Abstract] [Full Text] [PDF]


Home page
Proc. Natl. Acad. Sci. USAHome page
N. Leitinger, T. R. Tyner, L. Oslund, C. Rizza, G. Subbanagounder, H. Lee, P. T. Shih, N. Mackman, G. Tigyi, M. C. Territo, et al.
Structurally similar oxidized phospholipids differentially regulate endothelial binding of monocytes and neutrophils
PNAS, October 12, 1999; 96(21): 12010 - 12015.
[Abstract] [Full Text] [PDF]


Home page
Cardiovasc ResHome page
A. M Dart and J. P.F Chin-Dusting
Lipids and the endothelium
Cardiovasc Res, August 1, 1999; 43(2): 308 - 322.
[Abstract] [Full Text] [PDF]


Home page
J. Lipid Res.Home page
C. Balagopalakrishna, L. Paka, S. Pillarisetti, and I. J. Goldberg
Lipolysis-induced iron release from diferric transferrin: possible role of lipoprotein lipase in LDL oxidation
J. Lipid Res., July 1, 1999; 40(7): 1347 - 1356.
[Abstract] [Full Text]


Home page
FASEB J.Home page
P. K. WITTING, K. PETTERSSON, A.-M. ÖSTLUND-LINDQVIST, C. WESTERLUND, A. W. ERIKSSON, and R. STOCKER
Inhibition by a coantioxidant of aortic lipoprotein lipid peroxidation and atherosclerosis in apolipoprotein E and low density lipoprotein receptor gene double knockout mice
FASEB J, April 1, 1999; 13(6): 667 - 675.
[Abstract] [Full Text]


Home page
FASEB J.Home page
I. Suc, O. Meilhac, I. Lajoie-mazenc, J. Vandaele, G. Jürgens, R. Salvayre, and A. Nègre-salvayre
Activation of EGF receptor by oxidized LDL
FASEB J, June 1, 1998; 12(9): 665 - 671.
[Abstract] [Full Text]


Home page
FASEB J.Home page
H. E. De Vries, E. Ronken, J.-h. Reinders, B. Buchner, T. J. C. van berkel, and J. Kuiper
Acute effects of oxidized low density lipoprotein on metabolic responses in macrophages
FASEB J, January 1, 1998; 12(1): 111 - 118.
[Abstract] [Full Text]


Home page
Circ. Res.Home page
T. Komaru, T. Tanikawa, A. Sugimura, T. Kumagai, K. Sato, H. Kanatsuka, and K. Shirato
Mechanisms of Coronary Microvascular Dilation Induced by the Activation of Pertussis Toxin–Sensitive G Proteins Are Vessel-Size Dependent: Heterogeneous Involvement of Nitric Oxide Pathway and ATP-Sensitive K+ Channels
Circ. Res., January 1, 1997; 80(1): 1 - 10.
[Abstract] [Full Text]


Home page
Arterioscler. Thromb. Vasc. Bio.Home page
M. Navab, J. A. Berliner, A. D. Watson, S. Y. Hama, M. C. Territo, A. J. Lusis, D. M. Shih, B. J. Van Lenten, J. S. Frank, L. L. Demer, et al.
The Yin and Yang of Oxidation in the Development of the Fatty Streak: A Review Based on the 1994 George Lyman Duff Memorial Lecture
Arterioscler Thromb Vasc Biol, July 1, 1996; 16(7): 831 - 842.
[Abstract] [Full Text]


This Article
Right arrow Abstract Freely available
Right arrow Submit a response
Right arrow Alert me when this article is cited
Right arrow Alert me when eLetters are posted
Right arrow Alert me if a correction is posted
Right arrow Citation Map
Services
Right arrow Email this article to a friend
Right arrow Similar articles in this journal
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Download to citation manager
Right arrowRequest Permissions
Citing Articles
Right arrow Citing Articles via HighWire
Right arrow Citing Articles via Google Scholar
Google Scholar
Right arrow Articles by Parhami, F.
Right arrow Articles by Berliner, J. A.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Parhami, F.
Right arrow Articles by Berliner, J. A.